Navigation Links
Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
Date:5/5/2008

ANN ARBOR, Mich., May 5 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced a collaboration on a joint antibody research project with the Medical University of South Carolina and Dr. Jennifer Isaacs' laboratory. Under the terms of this agreement, Assay Designs will provide anti-Heat shock protein 90 (Hsp90) antibody for both cell-based and animal-based work.

This collaboration agreement will allow Dr. Isaacs to move forward with research investigating the role of Hsp90 in the progression of many cancers. "I am excited about the prospect of utilizing this antibody to target the Hsp90 chaperone and to potentially curtail the metastatic properties of some cancers. Moreover, we now have a new tool to explore the role of cell surface localized Hsp90 protein in cancer progression. Since this antibody is well-tolerated in animals, this approach paves the way for a promising therapeutic strategy, " stated Dr. Isaacs.

"As the leader in heat shock proteins (HSPs) and chaperones, collaborations such as this provide valuable insight for our new product development efforts," stated Dan Calvo, Assay Designs' President and CEO. "Supporting the validation of new and novel test protocols enhances the value and flexibility of our broad HSP product portfolio."

About Assay Designs, Inc.

Based in Ann Arbor, MI, Assay Designs develops, manufactures and markets immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company markets these products under the "Assay Designs" and "Stressgen" brand names. Researchers use Assay Designs products to detect and quantify molecules that are important biomarkers of inflammation, heat shock, cell signaling, and oxidative stress.

About Isaacs Lab.

A long-term research goal of the Isaacs Lab is to better understand the role of Hsp90 in tumor progression to ultimately optimize the use and potency of Hsp90 inhibitors in the clinic. In particular, the lab investigates how Hsp90 contributes to angiogenic processes and cell migration, representing two fundamental and universal aspects of cancer progression. Specifically, the tumor-promoting roles of Hsp90 are being assessed in various invasive cancers, such as prostate, renal cell carcinoma (RCC), and the deadly disease glioblastoma (GBM). Clinically relevant orthotopic models of RCC and GBM are being used and newer forms of Hsp90 antagonists are being evaluated. In collaboration with other groups, there is also interest in identifying combination treatments most effective against these cancers.


'/>"/>
SOURCE Assay Designs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
7. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
8. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
9. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
10. Study Reaffirms Superiority of Trofile(TM) Assay
11. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):